Glyburide Micronized and Ivacaftor and lumacaftor
Determining the interaction of Glyburide Micronized and Ivacaftor and lumacaftor and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor. The clinical relevance is unknown. MANAGEMENT: Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy. References "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. View all 4 references
Professional:MONITOR: Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor. The clinical relevance is unknown.
MANAGEMENT: Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.
- "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
Generic Name: glyburide
Brand name: DiaBeta, Glynase PresTab, Micronase, DiaBeta, Glynase
Synonyms: Glyburide, GlyBURIDE
Generic Name: ivacaftor / lumacaftor
Brand name: Orkambi
Synonyms: Lumacaftor and Ivacaftor
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Glyburide Micronized-Ivacaftor and tezacaftor
- Glyburide Micronized-Ivacaftor Granules
- Glyburide Micronized-Ivacaftor Tablets
- Glyburide Micronized-Ivermectin
- Glyburide Micronized-Ivermectin (Systemic)
- Glyburide Micronized-Ivermectin Cream
- Ivacaftor and lumacaftor-Glyburide Tablets
- Ivacaftor and lumacaftor-Glycate
- Ivacaftor and lumacaftor-Glycate Tablets
- Ivacaftor and lumacaftor-Glycerin and Lidocaine
- Ivacaftor and lumacaftor-Glycerin Enema
- Ivacaftor and lumacaftor-Glycerin rectal